What is the rate of dissolution of gallstones with Actigall (ursodiol) treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Rate of Gallstone Dissolution with Actigall (Ursodiol)

Actigall (ursodiol) requires 1 to 2 years of daily treatment to achieve complete gallstone dissolution in appropriately selected patients, with approximately 30% of unselected patients achieving complete dissolution and up to 50-81% success in optimal candidates with small, cholesterol-rich stones. 1

Treatment Duration and Success Rates

  • Complete stone dissolution can be anticipated in about 30% of unselected patients with uncalcified gallstones < 20 mm in maximal diameter treated for up to 2 years at a dose of approximately 10 mg/kg/day 1

  • The dissolution rate is significantly higher (up to 81%) in patients with very small stones (≤ 5 mm in diameter) 1

  • For patients with floating or floatable stones (high cholesterol content), the chance of dissolution increases up to 50% 1

  • Treatment duration typically ranges from 6 months to 2 years, with most patients requiring 1-2 years for complete dissolution 1, 2

Factors Affecting Dissolution Speed

  • Stone size is inversely related to dissolution success: stones up to 5 mm dissolve in 81% of cases, while stones > 20 mm rarely dissolve 1

  • Partial stone dissolution within 6 months predicts a > 70% chance of eventual complete dissolution with continued therapy 1

  • Partial dissolution observed within 1 year indicates a 40% probability of complete dissolution 1

  • Stones < 6 mm in diameter are best treated with oral bile acids alone and may achieve up to 75% complete dissolution annually with careful patient selection 3

Patient Selection Criteria for Optimal Results

  • Gallstones must be radiolucent (cholesterol-rich) and uncalcified 1, 3

  • The cystic duct must be patent, as indicated by gallbladder opacification on oral cholecystography 3

  • Patients with calcified gallstones prior to treatment, or those who develop stone calcification during treatment, rarely dissolve their stones 1

  • Gallbladder non-visualization developing during ursodiol treatment predicts failure of complete stone dissolution, and therapy should be discontinued in such cases 1

Important Limitations and Caveats

  • Ursodiol is generally limited to gallstones with diameter less than 1.5 cm 4

  • Age, sex, weight, degree of obesity, and serum cholesterol level are not related to the chance of stone dissolution 1

  • Stone recurrence occurs in approximately 30-50% of patients within 2-5 years after complete dissolution 1, 3, 5

  • Serial ultrasonographic examinations should be obtained to monitor for stone recurrence 1

Comparison to Alternative Therapies

  • Oral bile acids must be taken daily for up to 2 years, and because of their limited efficacy, their use is not widespread 4

  • Extracorporeal shock-wave lithotripsy combined with ursodiol achieves stone-free status in 21% of patients at 6 months (versus 9% with lithotripsy alone), with higher success rates (35%) for solitary radiolucent stones < 20 mm 6

  • Surgical removal (cholecystectomy) offers immediate and permanent stone removal, prevents future pain, complications, and gallstone recurrence, and is not limited by stone size or composition 4

Clinical Algorithm for Treatment Duration

  • Begin ursodiol at 8-10 mg/kg/day for optimal dissolution 1

  • Perform ultrasonography at 6 months: if partial dissolution is present, continue therapy with > 70% chance of complete dissolution 1

  • If no dissolution at 6 months, consider alternative therapy 1

  • Continue treatment for up to 2 years for complete dissolution in responsive patients 1, 2

  • After dissolution, monitor with serial ultrasound for recurrence, which may occur in 30-50% of patients within 2-5 years 1, 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.